Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study (Q33834247)

29 July 2017

title

Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study (English)

1 reference

29 July 2017

1 reference

1

John G Nutt

1 reference

29 July 2017

Kathy A Chung

2

1 reference

29 July 2017

Nicholas H G Holford

series ordinal

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

10 March 2010

1 reference

29 July 2017

1 reference

29 July 2017

volume

74

1 reference

29 July 2017

issue

15

1 reference

29 July 2017

page(s)

1191-1197

1 reference

Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

Opposite motor effects of pallidal stimulation in Parkinson's disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

The dopamine transporter: importance in Parkinson's disease

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

Evolution of the response to levodopa during the first 4 years of therapy.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

Pallidal stimulation for Parkinson's disease. Two targets?

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865731

29 October 2018

1 reference

12 December 2020

1 reference

12 December 2020

Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy

1 reference

12 December 2020

Young onset Parkinson's disease

1 reference

12 December 2020

Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon

1 reference

12 December 2020

Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease

1 reference

12 December 2020

A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease

1 reference

12 December 2020

Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease

1 reference

12 December 2020

Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and threshold

1 reference

12 December 2020

Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease

1 reference

12 December 2020

L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates

1 reference

12 December 2020

10.1212/WNL.0B013E3181D90050

Identifiers

DOI

1 reference

29 July 2017

1 reference

29 July 2017

1 reference